Post hoc individual-data analysis of 11 RCTs in 1781 biologic-naive ulcerative colitis patients with severe endoscopic disease: infliximab (35.1%) and upadacitinib (32.4%) had the highest week 2 PRO-2 response rates.
Meta-analysisn = 1,781
Wong et al. Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis With Severe Endoscopic Disease